With the US in regulatory limbo, Europe is winning the race to be the first regulated drugs market to approve generic copies of biotech drugs – despite the protests of the biotech pioneers who created them.
With the US in regulatory limbo, Europe is winning the race to be the first regulated drugs market to approve generic copies of biotech drugs – despite the protests of the biotech pioneers who created them.